MikeFit_NJ said:

For Needle length selection 4mm vs 6mm, here is what the evidence says:The clinical trial data (SUS

I respect MikeFit_NJ perspective but I think this oversimplifies things a bit. Re: Needle length selection 4mm — the effect size varies considerably by population.

I am not saying MikeFit_NJ wrong entirely — just that the picture is more nuanced than a blanket statement. The STEP data specifically shows dose-dependent variation.

Relevant to Needle length selection 4mm — here is my latest bloodwork comparison:

Key improvements: A1C 8.0% → 5.3%, triglycerides 191 → 91 mg/dL, hsCRP 6.0 → 0.9 mg/L. All on tirzepatide for 7 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you paige_pharma! This is incredibly helpful. Bookmarking for later. 🙏

Slightly tangential to Needle length selection but emma_london reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Reminder: nothing posted here constitutes medical advice. Consult your healthcare provider.

Tagging this for the weekly digest. 👍